Long-term safety of ketamine and esketamine in treatment of depression

References

• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr., Singh JB, Carlson PJ, et al. Manji HK: a randomized trial of an n-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864.
   PubMed Web of Science ®Google Scholar
• Kalsi SS, Wood DM, Dargan PI. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J. 2011;4(1):7107.
   PubMedGoogle Scholar
• Joe Laidler KA. The rise of club drugs in a heroin society: the case of Hong Kong. Subst Use Misuse. 2005;40(9–10):1257–1278.
   PubMed Web of Science ®Google Scholar
• Palamar JJ, Rutherford C, Keyes KM. Trends in ketamine use, exposures, and seizures in the United States up to 2019. Am J Public Health. 2021;111(11):2046–2049.
   PubMed Web of Science ®Google Scholar
• Cheng WJ, Chen CH, Chen CK, et al. Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia. Schizophr Res. 2018;199:313–318.
   PubMed Web of Science ®Google Scholar
• Xu K, Krystal JH, Ning Y, et al. Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia. J Psychiatr Res. 2015;61:64–72.
   PubMed Web of Science ®Google Scholar
• Kim J, Farchione T, Potter A, et al. Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class. N Engl J Med. 2019;381(1):1–4.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Salloum NC, Hock RS, et al. Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2020;81(4):19r12889.
   Web of Science ®Google Scholar
• Wajs E, Aluisio L, Holder R, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (sustain-2). J Clin Psychiatry. 2020;81(3):19m12891.
   Web of Science ®Google Scholar
• Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA psychiatry 2019.;76(9):893–903.
   Google Scholar
• Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-transform-3. Am J Geriatr Psychiatry. 2020;28(2):121–141.
   PubMed Web of Science ®Google Scholar
• Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (transform-1). int J Neuropsychopharmacol. 2019;22(10):616–630.
   PubMed Web of Science ®Google Scholar
• Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–438.
   PubMed Web of Science ®Google Scholar
• Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175(7):620–630.
   PubMed Web of Science ®Google Scholar
• Fu DJ, Ionescu DF, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020;81(3):19m13191.
   Web of Science ®Google Scholar
• Ionescu DF, Fu DJ, Qiu X, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol. 2020;24(1):22–31.
   Web of Science ®Google Scholar
• Cho H-S, D’Souza DC, Gueorguieva R, et al. Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology (Berl). 2005;179(1):136–143.
   PubMed Web of Science ®Google Scholar
• Becker A, Peters B, Schroeder H, et al. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(4):687–700.
   PubMed Web of Science ®Google Scholar
• Xu K, Lipsky RH. Repeated ketamine administration alters N -methyl- d -aspartic acid receptor subunit gene expression: implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans. Exp Biol Med (Maywood). 2015;240(2):145–155.
   PubMed Web of Science ®Google Scholar
• Quibell R, Fallon M, Mihalyo M, et al. Ketamine. J Pain Symptom Manage. 2015;50(2):268–278.
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Shovestul BJ, Jaso BA, et al. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J Affect Disord. 2018;232:310–315.
   PubMed Web of Science ®Google Scholar
• Chen G, Chen L, Zhang Y, et al. The relationship between dissociation and antidepressant effects of esketamine nasal spray in patients with treatment-resistant depression. int J Neuropsychopharmacol. 2022. DOI:10.1093/ijnp/pyab084
   Web of Science ®Google Scholar
• Muetzelfeldt L, Kamboj SK, Rees H, et al. Journey through the k-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95(3):219–229.
   PubMed Web of Science ®Google Scholar
• Sklar GS, Zukin SR, Reilly TA. Adverse reactions to ketamine anaesthesia. Abolition by a psychological technique. Anaesthesia. 1981;36(2):183–187.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Karper LP, Bennett A, et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl). 1998;135(3):213–229.
   PubMed Web of Science ®Google Scholar
• Sassano-Higgins S, Baron D, Juarez G, et al. Gold M: a review of ketamine abuse and diversion. Depress Anxiety. 2016;33(8):718–727.
   PubMed Web of Science ®Google Scholar
• Bokor G, Anderson PD. Ketamine: an update on its abuse. J Pharm Pract. 2014;27(6):582–586.
   PubMedGoogle Scholar
• Gili A, Bacci M, Aroni K, et al. Changes in drug use patterns during the covid-19 pandemic in Italy: monitoring a vulnerable group by hair analysis. Int J Environ Res Public Health. 2021;18(4):1967.
   PubMed Web of Science ®Google Scholar
• Cheng WC, Dao KL. Prevalence of drugs of abuse found in testing of illicit drug seizures and urinalysis of selected population in Hong Kong. Forensic Sci Int. 2019;299:6–16.
   PubMed Web of Science ®Google Scholar
• Li JH, Vicknasingam B, Cheung YW, et al. To use or not to use: an update on licit and illicit ketamine use. Subst Abuse Rehabil. 2011;2:11–20.
   PubMedGoogle Scholar
• Schak KM, Vande Voort JL, Johnson EK, et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry. 2016;173(3):215–218.
   PubMed Web of Science ®Google Scholar
• Roxas N, Ahuja C, Isom J, et al. A potential case of acute ketamine withdrawal: clinical implications for the treatment of refractory depression. Am J Psychiatry. 2021;178(7):588–591.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Rees H, Curran HV. Attentional bias to incentive stimuli in frequent ketamine users. Psychol Med. 2008;38(9):1331–1340.
   PubMed Web of Science ®Google Scholar
• Stewart CE. Ketamine as a street drug. Emerg Med Serv. 2001;30(32):34.
   Google Scholar
• Morgan CJ, Curran HV. Ketamine use: a review. Vol. 107. (Abingdon England): Addiction; 2012. p. 27–38.
   Google Scholar
• Morgan CJ, Dodds CM, Furby H, et al. Long-term heavy ketamine use is associated with spatial memory impairment and altered hippocampal activation. Front Psychiatry. 2014;5:149.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Vol. 105. (Abingdon England): Addiction; 2010. p. 121–133.
   Google Scholar
• Morgan CJ, Monaghan L, Curran HV. Beyond the k-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction. 2004;99(11):1450–1461.
   PubMed Web of Science ®Google Scholar
• Gill H, Gill B, Rodrigues NB, et al. The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research. Neurosci Biobehav Rev. 2021;120:78–85.
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Wright D, Fasula MK, et al. Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother Psychosom. 2017;86(3):162–167.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Wan LB, Iacoviello B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression, Association with antidepressant response. Psychopharmacology. 2013; DOI:10.1007/s00213-013-3255-x.
   Google Scholar
• Wilkinson ST, Rhee TG, Joormann J, et al. Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: a randomized clinical trial. Psychother Psychosom. 2021;90(5):318–327.
   PubMed Web of Science ®Google Scholar
• Katz EG, Hough D, Doherty T, et al. Benefit-risk assessment of esketamine nasal spray vs. Placebo in treatment-resistant depression. Clin Pharmacol Ther. 2021;109(2):536–546.
   PubMed Web of Science ®Google Scholar
• Szarmach J, Cubala WJ, Wlodarczyk A, et al. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. Psychiatr Danub. 2019;31(Suppl 3):585–590.
   PubMedGoogle Scholar
• Wilkinson ST, Toprak M, Turner MS, et al. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry. 2017;174(7):695–696.
   PubMed Web of Science ®Google Scholar
• O’Brien B, Wilkinson ST, Mathew SJ. An update on community ketamine practices. Am J Psychiatry.
   Web of Science ®Google Scholar
• Wilkinson ST, Katz RB, Toprak M, et al. Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale psychiatric hospital. J Clin Psychiatry. 2018;79(4). DOI:10.4088/JCP.17m11731
   PubMed Web of Science ®Google Scholar
• Short B, Fong J, Galvez V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65–78.
   PubMed Web of Science ®Google Scholar
• Spravato prescribing information - FDA label, 2019.
   Google Scholar
• Serinken M, Eken C. Ketamine may be related to minor troponin elevations in children undergoing minor procedures in the ed. Am J Emerg Med. 2015;33(7):904–906.
   PubMed Web of Science ®Google Scholar
• Doherty T, Wajs E, Melkote R, et al. Cardiac safety of esketamine nasal spray in treatment-resistant depression: results from the clinical development program. CNS Drugs. 2020;34(3):299–310.
   PubMed Web of Science ®Google Scholar
• Singh TSS, Elahi F, Cheney B. Ketamine-induced qtc interval prolongation. J Anaesthesiol Clin Pharmacol. 2017;33(1):136–138.
   PubMedGoogle Scholar
• Duan Q, Wu T, Yi X, et al. Changes to the bladder epithelial barrier are associated with ketamine-induced cystitis. Exp Ther Med. 2017;14(4):2757–2762.
   PubMed Web of Science ®Google Scholar
• Baker SC, Shabir S, Georgopoulos NT, et al. Ketamine-induced apoptosis in normal human urothelial cells: a direct, n-methyl-d-aspartate receptor-independent pathway characterized by mitochondrial stress. Am J Pathol. 2016;186(5):1267–1277.
   PubMed Web of Science ®Google Scholar
• Misra S, Chetwood A, Coker C, et al. Ketamine cystitis: practical considerations in management. Scand J Urol. 2014;48(5):482–488.
   PubMed Web of Science ®Google Scholar
• Cottrell A, Warren K, Ayres R, et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int. 2008;102:1178–1179. author reply 1179
   PubMed Web of Science ®Google Scholar
• Grégoire MC, MacLellan DL, Finley GA. A pediatric case of ketamine-associated cystitis (letter-to-the-editor re: Shahani r, streutker c, Dickson b, et al: ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69: 810-812, 2007). Urology. 2008;71(71):1232–1233.
   PubMedGoogle Scholar
• Shahani R, Streutker C, Dickson B, et al. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology. 2007;69(5):810–812.
   PubMed Web of Science ®Google Scholar
• Findeis H, Sauer C, Cleare A, et al. Urothelial toxicity of esketamine in the treatment of depression. Psychopharmacology (Berl). 2020;237(11):3295–3302.
   PubMed Web of Science ®Google Scholar
• Sun J, Lin J, Feng X, et al. Prenatal exposure to ketamine leads to anxiety-like behaviors and dysfunction in bed nucleus of stria terminalis. int J Neuropsychopharmacol. 2020;23(3):181–191.
   PubMed Web of Science ®Google Scholar
• Zhao T, Li Y, Wei W, et al. Ketamine administered to pregnant rats in the second trimester causes long-lasting behavioral disorders in offspring. Neurobiol Dis. 2014;68:145–155.
   PubMed Web of Science ®Google Scholar
• Komuro H, Rakic P. Modulation of neuronal migration by NMDA receptors. Science. 1993;260(5104):95–97.
   PubMed Web of Science ®Google Scholar
• Li X, Guo C, Li Y, et al. Ketamine administered pregnant rats impair learning and memory in offspring via the CREB pathway. Oncotarget. 2017;8(20):32433–32449.
   PubMedGoogle Scholar
• Su PH, Chang YZ, Chen JY. Infant with in utero ketamine exposure: quantitative measurement of residual dosage in hair. Pediatr Neonatol. 2010;51(5):279–284.
   PubMed Web of Science ®Google Scholar
• Dwyer JB, Landeros-Weisenberger A, Johnson JA, et al. Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial. Am J Psychiatry. 2021;178(4):352–362.
   PubMed Web of Science ®Google Scholar
• Lipsitz O, Di Vincenzo JD, Rodrigues NB, et al. Safety, tolerability, and real-world effectiveness of intravenous ketamine in older adults with treatment-resistant depression: a case series. Am J Geriatr Psychiatry. 2021;29(9):899–913.
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu RJ, et al. Mtor-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (New York, NY). 2010;329(5994):959–964.
   Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. Gould TD: nmdar inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481–486.
   PubMed Web of Science ®Google Scholar
• Williams NR, Heifets BD, Blasey C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175(12):1205–1215.
   Web of Science ®Google Scholar
• Sanacora G. Caution against overinterpreting opiate receptor stimulation as mediating antidepressant effects of ketamine. Am J Psychiatry. 2019;176(3):249.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Leenders KL, Oye I, et al. Differential psychopathology and patterns of cerebral glucose utilisation produced by (s)- and (r)-ketamine in healthy volunteers using positron emission tomography (pet). Eur Neuropsychopharmacol. 1997;7(1):25–38.
   PubMed Web of Science ®Google Scholar
• Correia-Melo FS, Leal GC, Vieira F, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. 2020;264:527–534.
   PubMed Web of Science ®Google Scholar
• Nikayin S, Rhee TG, Cunningham ME, et al. Evaluation of the trajectory of depression severity with ketamine and esketamine treatment in a real-world setting. JAMA Psychiatry. in press.
   Google Scholar
• Ketalar prescribing information - FDA Label, 2012.
   Google Scholar
• Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N- demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002;30(7):853–858.
   PubMed Web of Science ®Google Scholar
• Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of cyp2b6 in n-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2001;29(6):887–890.
   PubMed Web of Science ®Google Scholar
• Noppers I, Olofsen E, Niesters M, et al. Effect of rifampicin on s-ketamine and s-norketamine plasma concentrations in healthy volunteers after intravenous s-ketamine administration. Anesthesiology. 2011;114(6):1435–1445.
   PubMed Web of Science ®Google Scholar
• Peltoniemi MA, Saari TI, Hagelberg NM, et al. St john’s wort greatly decreases the plasma concentrations of oral s-ketamine. Fundam Clin Pharmacol. 2012;26(6):743–750.
   PubMed Web of Science ®Google Scholar
• Peltoniemi MA, Saari TI, Hagelberg NM, et al. S-ketamine concentrations are greatly increased by grapefruit juice. Eur J Clin Pharmacol. 2012;68(6):979–986.
   PubMed Web of Science ®Google Scholar
• Peltoniemi MA, Saari TI, Hagelberg NM, et al. Exposure to oral s-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther. 2011;90(2):296–302.
   PubMed Web of Science ®Google Scholar
• Kornhall D, Nielsen EW. Failure of ketamine anesthesia in a patient with lamotrigine overdose. Case Rep Crit Care. 2014;2014:916360.
   PubMedGoogle Scholar
• Huang MC, Chen LY, Chen CK, et al. Potential benefit of lamotrigine in managing ketamine use disorder. Med Hypotheses. 2016;87:97–100.
   PubMed Web of Science ®Google Scholar
• Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of n-methyl-d-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57(3):270–276.
   PubMed Web of Science ®Google Scholar
• Cusin C, Ionescu DF, Pavone KJ, et al. Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation. Aust N Z J Psychiatry. 2016;51(1):55–64.
   Web of Science ®Google Scholar
• Hu YD, Xiang YT, Fang JX, et al. Single i.V. Ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med. 2016;46(3):623–635.
   PubMed Web of Science ®Google Scholar
• Martin DC, Introna RP, Aronstam RS. Inhibition of neuronal 5-ht uptake by ketamine, but not halothane, involves disruption of substrate recognition by the transporter. Neurosci Lett. 1990;112(1):99–103.
   PubMed Web of Science ®Google Scholar
• Spies M, James GM, Berroterán-Infante N, et al. Assessment of ketamine binding of the serotonin transporter in humans with positron emission tomography. int J Neuropsychopharmacol. 2018;21(2):145–153.
   PubMed Web of Science ®Google Scholar
• Katz RB, Toprak M, Wilkinson ST, et al. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: a letter to the editor. Gen Hosp Psychiatry. 2018;54:62–64.
   PubMed Web of Science ®Google Scholar
• Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol. 2015;35(3):334–336.
   PubMed Web of Science ®Google Scholar
• Albott CS, Shiroma PR, Cullen KR, et al. The antidepressant effect of repeat dose intravenous ketamine is delayed by concurrent benzodiazepine use. J Clin Psychiatry. 2017;78(3):e308–e309.
   PubMed Web of Science ®Google Scholar
• Andrashko V, Novak T, Brunovsky M, et al. The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication. Front Psychiatry. 2020;11:844.
   PubMed Web of Science ®Google Scholar
• Schatzberg AF. A word to the wise about intranasal esketamine. Am J Psychiatry. 2019;176(6):422–424.
   PubMed Web of Science ®Google Scholar